Navigation Links
Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
Date:6/25/2009

WALTHAM, Mass., June 25 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, pharmacomechanical thrombectomy (PMT) procedure adoption will accelerate over the next five years due to growing physician interest in treating deep vein thrombosis (DVT). Although the ATTRACT (Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis) trial, which will compare catheter-directed thrombolysis (CDT) to PMT in the treatment of iliofemoral DVT, will not be completed until approximately 2014, early experience with PMT in this indication is promising. MRG's US Markets for Clot Management Devices 2009 report finds that PMT procedure volumes will thus undergo strong growth through 2013.

PMT procedures are still relatively new. Currently, four PMT devices are being used and/or investigated for the treatment of DVT: MEDRAD Interventional/Possis Medical's AngioJet Power Pulse Spray, Bacchus Vascular/Covidien's Trellis-8 Peripheral Infusion System, EKOS Corporation's EKOS EndoWave Peripheral Infusion System and ev3's Helix Clot Buster Thrombectomy Device. In order to address the clinical controversy regarding whether PMT should be routinely used as a first-line treatment for DVT, Possis Medical, Covidien, and EKOS are collaborating on the ATTRACT trial, which is slated to begin recruitment in July 2009.

"Firms are hoping that results of this trial will clarify the association between rapid clot lysis and the prevention of post-thrombotic syndrome in patients with proximal DVT, as well as demonstrate how PMT may have lower bleeding risks compared with traditional CDT alone," says Darren Navarro, Senior Analyst at MRG. "The reduced lytic doses and shorter treatment times in the intensive care unit afforded by PMT make this procedure safer and more user-friendly for the physician, and more convenient for the patient when compared to standard CDT."

MRG's US Markets for Clot Management Devices 2009 report provides important insight into the drug and device treatments of DVT and the complex competitive dynamics in this field. Additionally, the report provides market analyses for devices that treat arteriovenous, peripheral artery, coronary, and neurovascular thrombosis, including five-year forecasts, up-to-date market shares, and in-depth qualitative insights.

About Pharmacomechanical Thrombectomy

PMT is used predominantly for the treatment of iliofemoral DVT, but can also be used to a lesser extent in the treatment of upper limb DVT and peripheral artery occlusion. PMT combines the direct delivery of "clot-busting" thrombolytic drugs with mechanical clot disruption, and is posited to be safer, more effective, and more efficient than CDT alone due to the lower dose of thrombolytics required for clot dissolution.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ThromCat(R) XT(TM) Thrombectomy Catheter System Receives CE Mark
2. Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group
3. Thrombectomy Device Market to Approach $900 Million by 2013, According to Millennium Research Group
4. OMTECs Opening Keynote Emphasizes Increasing Demand for Orthopaedic Procedures
5. Dysport Added as a Procedure on AmericanHealthandBeauty.com: Let the Wrinkle Wars Begin
6. Kevin Niksarli, M.D. of Manhattan Lasik Center is to Discuss the iLASIK Procedure on AMWC Subspecialty Day Meeting on 7/1/2009
7. Simulation helps students learn dental implant procedures
8. TUG Procedure by Texas Health Dallas Cardiologist Offers Hope to Millions of Patients
9. Survey Reveals Injectable Procedures Are Mainstream And Accepted Medical Aesthetic Treatment Options
10. Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas
11. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... ... A stressful work environment can hurt the physical and emotional health of employees. ... workplace. The goal of Clearview Resolution Services has always been to help others, starting ... will be shutting down the office early on Fridays. The Clearview team will use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is ... the treatment of acute or chronic problems, I focus on preventative care with all my ... If you have any questions, always feel free to contact my office and my trained ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
(Date:4/24/2017)... Salt Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... in their efforts to encourage sustainability, innovate new strategies to reduce waste, and support ... all-natural herbal remedy provider. They look to nature to find solutions for health issues, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology: